StockData
ProKidney Corp. logo

ProKidney Corp. (PROK) stock

PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.10+0.06 (+5.77%)

Close on Nov 17, 2026Market cap $332.56MP/E –Yield –

ProKidney operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

ProKidney's operating income for the twelve months ending Jun 30, 2026 was -$177.22M. For fiscal 2025 it was -$165.01M. The highest annual figure on record is -$27.02M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$165.01M–
FY2024Dec 31, 2024-$183.68M–
FY2023Dec 31, 2023-$151.52M–
FY2022Dec 31, 2022-$153.01M–
FY2021Dec 31, 2021-$55.11M–
FY2020Dec 31, 2020-$27.02M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.37M–
Q1 FY2026Mar 31, 2026-$44.93M–
Q4 FY2025Dec 31, 2025-$45.37M–
Q3 FY2025Sep 30, 2025-$38.54M–
Q2 FY2025Jun 30, 2025-$39.71M–
Q1 FY2025Mar 31, 2025-$41.39M–
Q4 FY2024Dec 31, 2024-$51.57M–
Q3 FY2024Sep 30, 2024-$48.97M–
Q2 FY2024Jun 30, 2024-$43.06M–
Q1 FY2024Mar 31, 2024-$40.08M–
Q4 FY2023Dec 31, 2023-$24.21M–
Q3 FY2023Sep 30, 2023-$46.62M–
Q2 FY2023Jun 30, 2023-$39.82M–
Q1 FY2023Mar 31, 2023-$40.88M–
Q4 FY2022Dec 31, 2022-$30.24M–
Q3 FY2022Sep 30, 2022-$35.57M–
Q2 FY2022Jun 30, 2022-$20.74M–
Q1 FY2022Mar 31, 2022-$66.46M–
Q4 FY2021Dec 31, 2021-$13.71M–
Q3 FY2021Sep 30, 2021-$17.08M–
Q2 FY2021Jun 30, 2021-$143–

More ProKidney figures

See a number that looks wrong?